Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation : a systematic review and meta-analysis of phase III randomized clinical trials
INTRODUCTION: Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation.
METHODS: Online databases were comprehensively searched for all phase III Randomized trials that used Rucaparib therapy for ovarian cancer patients and patients having BRCA mutation. Efficacy results are progression-free survival and overall response rate in addition to addressing its safety concerns.
RESULTS: After pooling data from 4 clinical trials, the analysis showed a significant improvement in PFS among ovarian cancer patients and for the maintenance therapy with a hazard ratio (HR) of 0.49 (95% CI 0.34-0.73, p = 0.0003) and 0.42 (95% CI 0.29-0.62, p < 0.0001), respectively. For patients with BRCA mutations, the PFS showed significant improvement with a (HR) of 0.42 (95% CI 0.25-0.71, p < 0.001). A difference was observed in the risk of grade ≥ 3 TEAEs between the two groups (RR = 2.48; 95% CI 1.40-4.37).
CONCLUSION: Rucaparib demonstrated significant efficacy in improving PFS and ORR in ovarian cancer patients, particularly those having BRCA mutations. However, they should be closely monitored due to the greater risk of various adverse effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 24(2024), 1-2 vom: 15. Jan., Seite 71-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mustafa, Mus'ab Theeb [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8237F3U7EH |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2024.2309177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36742519X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36742519X | ||
| 003 | DE-627 | ||
| 005 | 20240214233136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2024.2309177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM36742519X | ||
| 035 | |a (NLM)38252024 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mustafa, Mus'ab Theeb |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation |b a systematic review and meta-analysis of phase III randomized clinical trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation | ||
| 520 | |a METHODS: Online databases were comprehensively searched for all phase III Randomized trials that used Rucaparib therapy for ovarian cancer patients and patients having BRCA mutation. Efficacy results are progression-free survival and overall response rate in addition to addressing its safety concerns | ||
| 520 | |a RESULTS: After pooling data from 4 clinical trials, the analysis showed a significant improvement in PFS among ovarian cancer patients and for the maintenance therapy with a hazard ratio (HR) of 0.49 (95% CI 0.34-0.73, p = 0.0003) and 0.42 (95% CI 0.29-0.62, p < 0.0001), respectively. For patients with BRCA mutations, the PFS showed significant improvement with a (HR) of 0.42 (95% CI 0.25-0.71, p < 0.001). A difference was observed in the risk of grade ≥ 3 TEAEs between the two groups (RR = 2.48; 95% CI 1.40-4.37) | ||
| 520 | |a CONCLUSION: Rucaparib demonstrated significant efficacy in improving PFS and ORR in ovarian cancer patients, particularly those having BRCA mutations. However, they should be closely monitored due to the greater risk of various adverse effects | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRCA mutation | |
| 650 | 4 | |a PARPi | |
| 650 | 4 | |a Rucaparib | |
| 650 | 4 | |a meta analysis | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a prostate cancer | |
| 650 | 7 | |a rucaparib |2 NLM | |
| 650 | 7 | |a 8237F3U7EH |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 700 | 1 | |a Abushanab, Aws Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Mousa, Mahmoud Taysir |e verfasserin |4 aut | |
| 700 | 1 | |a Qawaqzeh, Rana Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Alakhras, Hamza Muneer |e verfasserin |4 aut | |
| 700 | 1 | |a Othman, Ahmad Sami |e verfasserin |4 aut | |
| 700 | 1 | |a Sa'ed, Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 24(2024), 1-2 vom: 15. Jan., Seite 71-79 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1-2 |g day:15 |g month:01 |g pages:71-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2024.2309177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1-2 |b 15 |c 01 |h 71-79 | ||